Last reviewed · How we verify
BR9003A
At a glance
| Generic name | BR9003A |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multi Doses Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects (PHASE1)
- A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR9003A CI brief — competitive landscape report
- BR9003A updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI